Prime Medicine Inc. (PRME)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why
PRME shares jump nearly 26% in a month as FDA clearance for PM647 and PM577a's clinical debut advances its gene-editing pipeline.
Prime Medicine: Soon In The Clinic
Prime Medicine trades at a $548M valuation, significantly undervaluing its broad, potentially best-in-class gene-editing pipeline. PRME's therapies target five indications across liver, lung, and immunology/oncology, with leading preclinical efficacy and multi-billion-dollar addressable markets. Recent IND/CTA clearances, RMAT designation, and patent wins highlight PRME's clinical and strategic momentum despite a 54% stock decline from 52-week highs.
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.41 per share a year ago.
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Prime Medicine, Inc. (PRME) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers precise, versatile gene correction using LNP delivery, but remains preclinical with IND/CTA filings for PM647 expected mid-2026 and initial clinical data in 2027. PRME lags competitors like Beam, Sanofi, and Arrowhead in the AATD development race, facing significant funding needs and clinical risks.
Prime Medicine's Prime Editing Is Worth The Risk
Prime Medicine's PM359 data gives the stock some early human validation for its main value driver: Prime Editing. PM359 was essentially their most advanced application of Prime Editing, even though CGD is a relatively niche market because it's a rare disease. Management decided to deprioritize PM359, and instead, it's now focused on applying Prime Editing towards larger TAMs like Wilson Disease and AATD.
Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Prime Medicine, Inc. (PRME) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.4 per share a year ago.
Prime Medicine (NASDAQ:PRME) & AgomAb Therapeutics (NASDAQ:AGMB) Critical Survey
Prime Medicine (NASDAQ: PRME - Get Free Report) and AgomAb Therapeutics (NASDAQ: AGMB - Get Free Report) are both small-cap manufacturing companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, institutional ownership and valuation. Valuation and Earnings This table compares Prime
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Prime Medicine, Inc. (PRME) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.31 per share a year ago.
Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Prime Medicine, Inc. (PRME) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
